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4University of Calgary, Calgary, AB, CanadaA B S T R A C TObjectives: Rising out-of-pocket costs for cancer patients have
increased shared decision making. Clinical guidelines recommend
prophylactic granulocyte colony-stimulating factor (G-CSF) for
patients receiving chemotherapy with a 20% or greater risk of febrile
neutropenia. A discrete choice experiment was conducted to explore
breast cancer patients’ preferences and willingness to pay (WTP) for
prophylactic G-CSF to decrease the risk of chemotherapy-induced
febrile neutropenia. Methods: An online discrete choice experi-
ment questionnaire survey of a national US convenience sample
of self-reported breast cancer patients with prior chemotherapy
treatment was conducted. Sixteen paired G-CSF treatment scenar-
ios, each with four attributes (risk of disruption to chemotherapy
schedule due to low white blood cell counts, risk of developing an
infection requiring hospitalization, frequency of administration,
and total out-of-pocket cost) were presented with a follow-up “no
treatment” option. Participant preferences and WTP out of pocket
were estimated by logistic regression. Results: Participants (n ¼
296) preferred G-CSF regimens with lower out-of-pocket costs,see front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2014.01.002
johnson@optum.com.
ndence to: Phaedra Johnson, OptumInsight, 12125lower risk of chemotherapy disruption, lower risk of infection,
and greater convenience (one G-CSF injection per chemotherapy
cycle). Participants’WTP was $1076 out of pocket per cycle to reduce
the risk (high to low) of disrupting their chemotherapy schedule,
$884 per cycle to reduce the risk (24% [high] to 7% [low]) of infection,
and $851 per cycle to decrease the number of G-CSF injections (11 to
1) per cycle. Conclusions: Participants highly valued speciﬁc fea-
tures of prophylactic G-CSF treatment including maintaining their
chemotherapy schedule, lowering their risk of infection, and reduc-
ing the number of injections. Physicians should consider patient
preferences to inform the best treatment choices for individual
patients.
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Myelosuppressive chemotherapy can result in neutropenia with
infection (febrile neutropenia [FN]), which may lead to hospital-
ization and treatment with broad-spectrum antibiotics. FN can
also lead to high health care costs due to inpatient admissions [1–
5]. In addition, severe neutropenia and FN can result in chemo-
therapy dose delays and reductions, thereby reducing relative
dose intensity and compromising patient outcomes [6–8].
The recombinant granulocyte colony-stimulating factors (G-
CSF) ﬁlgrastim and pegﬁlgrastim are indicated to decrease the
incidence of infection, as manifested by FN, in patients with
nonmyeloid malignancies receiving myelosuppressive chemo-
therapy [9,10]. Filgrastim, which undergoes renal clearance, has
a half-life of 3.5 hours and requires daily administration with
each chemotherapy cycle [11], whereas pegﬁlgrastim, which
undergoes neutrophil-mediated clearance, has a longer half-life
and requires a single ﬁxed dose with each cycle [12–14].Prophylaxis with ﬁlgrastim or pegﬁlgrastim shortens the severity
and duration of chemotherapy-induced neutropenia, reduces the
incidence of FN and FN-related hospitalizations, and reduces the
need for antibiotics [11–20]. Current clinical guidelines recom-
mend primary prophylaxis with G-CSF when a patient’s risk of FN
associated with myelosuppressive chemotherapy is 20% or more
[21,22]. Randomized clinical trials have demonstrated that once-
per-cycle pegﬁlgrastim is noninferior to ﬁlgrastim (when admin-
istered for 10–11 days) in reducing the incidence of FN [12,13]. In
clinical practice, however, ﬁlgrastim is often administered for
fewer days (e.g., 4–6 days) than determined to be effective in
clinical trials [23–27]. Although shorter courses of ﬁlgrastim may
reduce costs related to G-CSF treatment, they can also lead to an
increased risk of FN and FN-related hospitalizations, thereby
increasing the overall cost of treatment [23–27].
The rising cost of health care in the United States has led to a
shift toward higher out-of-pocket costs for cancer patients; and
for some patients this has resulted in bankruptcy [28]. A survey ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Technology Drive, Eden Prairie, MN 55344.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 8 0 – 3 8 9 381breast cancer patients with health insurance found that patients
were paying an average monthly out-of-pocket cost of $597 (2004
dollars) in total direct medical costs (e.g., nonreimbursed hospital
bills and physician visits) [29]. A more recent study found that
cancer patients who received chemotherapy with G-CSF therapy
in an outpatient setting paid mean quarterly out-of-pocket costs
of $100 to $150 for pegﬁlgrastim and $50 to $100 for ﬁlgrastim
(2010 dollars) [30]. Because patients are now assuming more of
the cost burden and are becoming more involved in treatment
decisions, more attention is being given to their preferences for
treatment options. The move toward patient-centered care has
been demonstrated in the United States by the establishment of
the Federal Coordinating Council for Comparative Effectiveness
Research [31] and the Patient Centered Outcomes Research
Institute [32].
Using a discrete choice experiment (DCE), a speciﬁc conjoint
analysis elicitation format, we estimated preferences and
willingness to pay (WTP) for prophylactic G-CSF to reduce the
incidence of chemotherapy-induced FN among self-reported
breast cancer patients with a history of chemotherapy treatment.
The primary purpose of our study was to understand how
patients value speciﬁc characteristics of prophylactic G-CSF treat-
ment options.Table 1 – Final attributes and attribute levels in the
conjoint analysis survey.
Attribute* Levels
Risk of disruption to
chemotherapy schedule
due to low white blood cell
counts (neutropenia)†
Low
Moderate
High
Risk of developing an
infection requiring
hospitalization‡
7%
17%
24%
Frequency of G-CSF
administration§
1 injection per chemotherapy
cycle administered at the
clinic 24 h after
chemotherapy‖
6 injections per chemotherapy
cycle administered daily at
the clinic beginning 24 h
after chemotherapy for 6 d¶
11 injections per chemotherapy
cycle administered daily at
the clinic beginning 24 h
after chemotherapy for 11 d#
Total out-of-pocket cost for G-
CSF support per
chemotherapy cycle**
$50
$250
$500
$1000
$1500
G-CSF, granulocyte colony-stimulating factor.
* Attribute descriptions modiﬁed from those presented to the
participants.
† Includes chemotherapy dose reductions and dose delays.
‡ Levels were based on data from Martin et al. [37,38] and von
Minckwitz et al. [39].
§ Injections per cycle.
‖ Based on data from Green et al. [12], Holmes et al. [13], and Vogel
et al. [14].
¶ Based on data from Morrison et al. [23] and Weycker et al. [24,27].
# Based on data from Green et al. [12] and Holmes et al. [13].
** Includes all injections.Methods
Development of the DCE
Conjoint analysis can be used to measure patient preferences in
the face of risk/beneﬁt trade-offs among treatment options.
Conjoint analysis decomposes an intervention into its key attrib-
utes to derive patient-determined values for each attribute
[33,34]. Good practice guidelines for conjoint analysis in health
care, including DCEs, state that attributes and attribute levels
developed for discrete choice tasks must be supported by evi-
dence [35,36]. Accordingly, we conducted a literature review,
consulted with four clinicians, and held in-depth interviews with
six breast cancer patients who had previously received chemo-
therapy to develop an initial list of attributes associated with
prophylactic G-CSF support. Attributes that were likely independ-
ent (did not overlap in meaning with other attributes and
preferences for a change in the level of one attribute did not
depend on the level of a different attribute) provided clear
differentiation among G-CSF treatment options, and were mean-
ingful to breast cancer patients, were selected for inclusion in a
pilot DCE survey. Five attributes that met these criteria were
identiﬁed as follows: risk of disruption to chemotherapy schedule
(i.e., dose reduction/delay) due to low white blood cell counts
(neutropenia), risk of developing an infection requiring hospital-
ization, frequency of G-CSF administration, inconvenience of G-
CSF administration, and total out-of-pocket cost for G-CSF (all
injections) during a chemotherapy cycle. For each attribute, we
identiﬁed levels that were plausible, relevant, and clear in their
meaning. For example, values for FN risk in the attribute “risk of
developing an infection requiring hospitalization” were based on
studies of breast cancer patients who had received docetaxel/
doxorubicin/cyclophosphamide [37–39].
Sawtooth Software’s (Orem, UT) SSI Web application was used
for designing and hosting the Internet survey with the choice-
based conjoint platform for a full proﬁle design. Sawtooth Soft-
ware implements randomized experimental designs that are
close to optimally efﬁcient. Following good research practices
for conjoint experimental design, we evaluated and selected the
best design given the number of attributes and levels. We
considered correlations to maximize orthogonality (all attribute
levels vary independently and are not correlated), the highestD-efﬁciency (smallest variance matrix), and the greatest level
balance (each level of an attribute occurs the same number of
times).
We pretested the survey with four previously treated breast
cancer patients who were members of an opt-in survey panel,
and subsequently pilot tested the survey (see Appendix 1 in
Supplemental Materials at found at http://dx.doi.org/10.1016/j.
jval.2014.01.002) with 32 panelists to determine the feasibility of
the DCE and to reﬁne the survey instrument. The pilot survey
results indicated that the attribute “inconvenience of G-CSF
administration” had the least effect on participants’ choices
and was likely not independent of the “frequency of treatment”
attribute; this attribute was excluded from the ﬁnal survey. The
ﬁnal DCE (a fractional factorial design) included the four remain-
ing attributes, with each comprising three to ﬁve levels (Table 1)
[40].
The ﬁnal survey instrument (see Appendix 2 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.01.002)
contained ﬁve sections: 1) screening questions, 2) clinical char-
acteristics and health care costs questions, 3) discrete choice
tasks, 4) attitudinal and awareness questions, and 5) demo-
graphic characteristics questions. Participants were asked to
complete a sample choice task before completing 16 choice tasks,
which were randomly generated for each participant; an example
Fig. 1 – Example choice task question in the discrete choice experiment. This ﬁgure is representative of one choice task set.
The levels within each attribute change from one choice task set to the next.
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to choose which of two treatments they preferred and, in a
follow-up question, whether they would prefer the treatment
they selected versus “no treatment.” The treatment options were
displayed as “Treatment 1” or “Treatment 2” and did not refer to
brand or generic names. Each scenario presented all four
attributes based on the experimental design, which accounted
for implausible combinations of treatment regimens. The “fre-
quency of G-CSF administration” presented the corresponding
number of injections required for each treatment option (1 dose
per cycle [pegﬁlgrastim], 6 doses per cycle [ﬁlgrastim], or 11
doses per cycle [ﬁlgrastim]). Peoplegrams (visual represen-
tation using people images; see Fig. 1) were used to present
the levels for “risk of developing an infection requiring hospital-
ization”; this decision was guided by ﬁndings from the qual-
itative phase. Because precise estimates were not found in the
published literature for “risk of disruption to chemotherapy
schedule,” levels were presented as low, moderate, or high [41–
43].
Survey Administration
Three global online panel providers (Survey Sampling Interna-
tional; Opinionology, LLC; and Research Now) identiﬁed potential
participants. The Internet survey panels included individuals
living in the United States who had previously been chosen and
invited to participate in health/other surveys. Eligible participants
were self-reported to be women who were 18 years or older, US
residents, and who had been diagnosed with breast cancer and
received chemotherapy for breast cancer within the past 5 years.Participants were excluded if they had participated in the pilot
survey.
An invitation e-mail containing a link to the survey was sent
by the panel providers to potential study participants. Partici-
pants were required to complete screening questions before
starting the survey to determine eligibility. Participants who
completed the survey were directed back to the panel provider
Web sites to conﬁrm participation in the study. The survey was
estimated to take 15 to 20 minutes to complete. Participants were
required to complete all choice tasks in addition to providing
responses to the other survey questions (e.g., clinical and attitu-
dinal questions) for the survey to be considered complete. After
306 surveys were completed, the survey Web sites closed.
Participants received a $20 check for their time and effort. The
study was approved by the New England Institutional Review
Board, and participants provided electronic informed consent.
Statistical Analysis
Participants’ demographic and clinical characteristics, health
care costs, attitudinal and awareness questions, and survey
completion data were analyzed descriptively using means  SD,
medians, and ranges (minimum and maximum) for continuous
variables and counts (percent) for categorical variables.
DCE Preference Estimation
A multinomial logistic regression model, also referred to as a
conditional logistic regression model, was used to model the
choice task data, which included an “opt-out” option. Using
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worth utilities (preference weights) were estimated via maximum
likelihood for all main effects (the effect of each attribute on
treatment choice measured independently of the other attrib-
utes). While there are multiple responses per respondent, the
software does not allow for this adjustment; therefore, all choice
task responses were treated as independent. All attributes were
coded as categorical variables with the exception of out-of-pocket
cost. Out-of-pocket cost was initially included as a categorical
variable, but a plot of the estimated parameter coefﬁcients
against the corresponding levels indicated that a linear relation-
ship was adequate. Hence, out-of-pocket cost was ultimately
included as a continuous term in the analysis.
Relative importance was determined by ﬁrst rescaling the
attribute with the largest range of preference weights among its
levels from 0 (attribute level with the lowest preference weight) to
10 (attribute level with the highest preference weight). The other
attribute levels were then rescaled accordingly; for each attribute,
the attribute level with the lowest preference weight was set to 0.
The relative attribute level preference weights were used to
calculate the overall relative importance of each attribute
included in the choice task questions and the rate at which
participants were willing to trade-off between a change in the
levels of one attribute versus another.
WTP Estimation
Estimates of WTP to switch between two levels of a given
attribute (other than cost) were derived by ﬁrst ﬁnding the
difference in estimated utility between those two attribute levels
(the difference in preference weights). WTP to switch between
those two levels was estimated by determining the change in
out-of-pocket cost required to obtain an equivalent utility
change. Results for WTP were rounded to the nearest US dollar.
Separate multinomial logistic regression models and a chi-square
test were used to analyze the WTP of selected participant
subgroups based on age, employment status, and experience of
FN (without adjustment for multiplicity). Missing responses due
to skip patterns and “I don’t remember/don’t know” responses
were omitted from the subgroup analysis.
A sensitivity analysis was conducted to obtain income-
speciﬁc utilities of cost because a participant’s income could
affect WTP. Participants’ income was collected categorically, and
the categories were interacted with cost using the same multi-
nomial logistic regression model.
Validity and Sensitivity Analyses
We examined the internal validity of participants’ responses to
the discrete choice tasks by ﬁrst conducting a hierarchical
Bayesian analysis to estimate individual-level preference
weights, and then calculating Root LikeliHood (RLH) to determine
the individual-level predictability of participants’ responses.
Participants with an RLH of less than 500 were identiﬁed as likely
inconsistent responders (responses did not match the repeated
choice tasks).
A sensitivity analysis was conducted to determine the effect
of inconsistent responses on the DCE. The aggregate preference
weights for all participants and the subset with an RLH of 500 or
more were compared, and the relative goodness of ﬁt of the
models was evaluated using the Akaike information criterion and
percent certainty.Results
A total of 524,056 invitations to participate in the survey were
delivered, and 4,186 (0.8%) responded, 2,108 of whom wereineligible to participate based on their responses to the screening
questions. Of the remaining 1,749 eligible respondents, 306 fully
and 23 partially completed the survey. The median survey
completion time for the fully completed surveys was 17 (range,
3.4–491) minutes.
Validity and Sensitivity Analysis
Of the 306 participants with fully completed surveys, 296 (97%)
were identiﬁed with an RLH of 500 or more and 10 (3%) with an
RLH of less than 500. Participants with an RLH of less than 500
versus those with an RLH of 500 or more had shorter median
survey completion times (9.7 [range, 3.4–18.9] vs. 17.3 [range, 4.1–
491] minutes) and selected the left and right options 68% and 32%
of the time versus 52% and 48% of the time, respectively. A
sensitivity analysis comparing the aggregate preference weights
for all participants and the subset with an RLH of 500 or more
demonstrated that the Akaike information criterion decreased by
approximately 4% and the percent certainty increased by approx-
imately 5% when the participants with an RLH of less than 500
were excluded (results not shown). In addition, the parameter
estimates had larger ranges across attribute levels when partic-
ipants with an RLH of less than 500 were excluded. Therefore, the
10 participants with an RLH of less than 500 were excluded from
the analysis because of likely inconsistent responses.
Participant Characteristics
The demographic and clinical characteristics of the 296 partic-
ipants are shown in Table 2. Approximately half of the partic-
ipants reported that they were 45 to 64 years old (56%) and most
were white (86%). Most participants reported that they were
initially diagnosed with stage I or II breast cancer (72%), and
about one-third indicated that their cancer had metastasized
(31%) either at the time of their initial diagnosis or after their
initial diagnosis.
A total of 163 (55%) participants reported that they had
experienced neutropenia, of whom 68 (42%) had experienced
FN. A total of 211 (71%) participants received G-CSF therapy
(ﬁlgrastim, n ¼ 34; pegﬁlgrastim, n ¼ 117).
Most of the participants reported a household income of less
than $100,000 (76%), and most had insurance coverage (private or
public, 98%). A total of 251 (85%) participants were charged a co-
payment or co-insurance fee. Participants reported a median of
three (range, 0–50) medications per month and incurred median
out-of-pocket costs of $50 (range, $0–$2500) and $80 (range, $0–
$7000) for medications and ofﬁce visits, respectively, while
receiving chemotherapy for breast cancer. Among participants
who received prophylactic G-CSF support, 165 responded that
their median out-of-pocket cost for each injection or shot series
(ﬁlgrastim or pegﬁlgrastim) was $4 (range, $0–$1000).
Participants’ Attitudes Toward, and Awareness of, FN Risk
A total of 267 (90%) and 220 (74%) participants responded that
they believe individuals who undergo chemotherapy are at risk of
developing neutropenia and FN, respectively, and 198 (67%)
reported that they personally have been/are at risk for developing
neutropenia as a side effect of chemotherapy. Most of the
participants (95%) believed that developing either neutropenia
or FN can be a very serious problem.
Inconvenience of Additional Travel
Forty-three (15%), 139 (47%), and 200 (68%) participants responded
that it would be either very or extremely inconvenient to travel to
the clinic once, 6 times, or 11 times, respectively, every chemo-
therapy cycle in addition to their other clinic visits to receive an
Table 2 – Participant characteristics.
Characteristics Participants
who answered
the question,
N
Participants
who chose
each category,
n (%)
Demographic
Age (y) 296
18–44 87 (29)
45–64 165 (56)
65þ y 44 (15)
Region* 296
Northeast 56 (19)
Midwest 88 (30)
South 94 (32)
West 58 (20)
Race 296
White† 254 (86)
Black 25 (8)
Other 17 (6)
Marital status 296
Married 171 (58)
Not married 125 (42)
Education 296
Attended college 239 (81)
Did not attend
college
57 (19)
Employment status* 296
Full-time 116 (39)
Part-time 34 (11)
Unemployed 146 (49)
Household income ($) 296
o49,999 121 (41)
50,000–99,999 103 (35)
Z100,000 or more 54 (18)
Participant did not
know
18 (6)
Insurance type 296
Commercial alone 186 (63)
Commercial and
other coverage
28 (9)
Medicare alone 32 (11)
Medicaid alone 20 (7)
Medicare and
Medicaid dual
coverage
13 (4)
Federal Employee
Health Beneﬁts
10 (3)
No coverage 6 (2)
I do not remember/
do not know
1 (o1)
Clinical characteristics
and history
Months since breast
cancer diagnosis,
mean  SD
289‡ 31  17
Months since last
chemotherapy
treatment for breast
cancer, mean  SD
272§ 23  17
Disease stage at initial
diagnosis*
296
Stage I or II (IIA, IIB) 212 (72)
Stage III (IIIA, IIIB,
IIIC)
62 (21)
Table 2 – continued
Characteristics Participants
who answered
the question,
N
Participants
who chose
each category,
n (%)
Stage IV 8 (3)
I do not remember/
do not know
14 (5)
Cancer spread to other
parts of the body
296
Yes 92 (31)
No 204 (69)
Currently undergoing
treatment for breast
cancer
296
Yes 167 (56)
No 129 (44)
Currently receiving
chemotherapy alone
or in combination
with other therapies
166‖ 47 (28)
Health care provider
discussed FN as a
side effect of
chemotherapy
296
Yes 248 (84)
No 31 (10)
I do not remember/
do not know
17 (6)
Neutropenia
experience
296
Yes 163 (55)
No 109 (37)
I do not remember/
do not know
24 (8)
FN experience 163
Yes 68 (42)
No 91 (56)
I do not remember/
do not know
4 (2)
Prior chemotherapy
dose reduction or
dose delay due to FN
68
Yes 47 (69)
No 21 (31)
I do not remember/
do not know
0 (0)
Prior hospitalization
due to FN
68
Yes 44 (65)
No 22 (32)
I do not remember/
do not know
2 (3)
Received white blood
cell booster
296
Yes 211 (71)
No 70 (24)
I do not remember/
do not know
15 (5)
Name of white blood
cell booster
211
Filgrastim 34 (16)
Continued on next page
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Table 2 – continued
Characteristics Participants
who answered
the question,
N
Participants
who chose
each category,
n (%)
Pegﬁlgrastim 117 (55)
Sargramostim 8 (4)
Antibiotics 11 (5)
Other 4 (2)
I do not remember/
do not know
37 (18)
Health care costs
Charged co-payment
or co-insurance
296
Yes 251 (85)
I do not have
insurance
coverage
15 (5)
I do not remember/
do not know
30 (10)
Participant out-of-
pocket costs while
undergoing
chemotherapy ($),
median (range)
Monthly out-of-
pocket costs for all
prescription
medications
228¶ 50 (0–2500)
Monthly out-of-
pocket costs for all
ofﬁce visits
241¶ 80 (0–7000)
Out-of-pocket costs
for each injection
or series of G-CSF
165¶ 4 (0–1000)
FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating
factor.
* Percentages do not add up to 100% because of rounding.
† Includes 20 participants who indicated they were Hispanic.
‡ Seven participants did not remember/did not know when they
were diagnosed with breast cancer.
§ Twenty-four participants did not remember/did not know the
time since their last chemotherapy treatment for breast cancer.
‖ One participant did not remember/did not know whether he or
she was currently receiving chemotherapy.
¶ Represents the number of participants who provided nonmissing
responses to the survey question.
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counts.
Participant Preferences for G-CSF Treatment
Table 3 shows participants’ preference ratings for the attributes
and levels that characterized the treatment options in the DCE as
estimated preference weights. Consistent with a priori expect-
ations, participants preferred G-CSF regimens with 1) the lowest
total out-of-pocket costs; 2) improved clinical outcomes (lower risk
of disruption to their chemotherapy schedule and lower risk of an
infection requiring hospitalization); and 3) greater convenience
(one G-CSF injection per chemotherapy cycle). The preference
weights for the attribute levels followed logical ordering (i.e.,
lowest costs, lowest risks, and least inconvenience were preferred).
The relative importance of the attributes over the range of
levels included in this DCE show that total out-of-pocket cost andrisk of disruption to chemotherapy schedule were the most
important attributes to participants (Fig. 2). In the context of this
study, the attributes “risk of developing an infection requiring
hospitalization” and “frequency of injection” inﬂuenced partic-
ipants’ choice of G-CSF regimen to a smaller, but similar degree.WTP Estimates
Participants were asked to choose how much they would be
willing to pay out of pocket per chemotherapy cycle for “Treat-
ment 1” versus “Treatment 2” in each choice task. Participants
were willing to pay the most out of pocket to reduce the risk of
disrupting the chemotherapy schedule from high to low ($1076
per cycle), and a similar amount to reduce the risk of developing
an infection requiring hospitalization from 24% (high) to 7% (low)
and to decrease the number of G-CSF injections per chemo-
therapy cycle from 11 to 1 ($884 and $851 per cycle, respectively)
(Table 4).
There were notable differences among participant subgroups
in their WTP for speciﬁc attributes (Table 4). When compared by
age, participants aged 18 to 44 years were willing to pay the most
out of pocket to decrease disruption to their chemotherapy
schedule from high to low ($1466 per cycle) and participants
aged 65 years or older were willing to pay the most out of pocket
to reduce the risk of developing an infection requiring hospital-
ization from 24% to 7% ($1101 per cycle). Participants employed
full-time were willing to pay more out of pocket to reduce the risk
of disruption to the chemotherapy schedule from high to low
compared with participants employed part-time or who were
unemployed ($1820, $512, and $771 per cycle, respectively).
Among participants who had experienced neutropenia while
undergoing chemotherapy, those who had experienced FN were
willing to pay less out of pocket compared with those who had
not experienced FN to decrease disruption to the chemotherapy
schedule from high to low ($830 vs. $1002 per cycle) and to reduce
the risk of developing an infection requiring hospitalization from
24% to 7% ($443 vs. $927 per cycle).
The estimated utility of cost per $1000 was signiﬁcantly
different across income categories (likelihood ratio test statistic
¼ 28.2075; df ¼ 6; P o 0.0001), with estimated utilities of cost
ranging from 0.349 for participants whose reported income was
$125,000 or more to 0.964 for participants whose reported
income was between $25,000 and $50,000.Discussion
This study was conducted to estimate US breast cancer patients’
preferences and WTP for prophylactic G-CSF and to understand
how these patients value speciﬁc features of G-CSF regimens. As
expected, participants preferred regimens with lower out-of-
pocket costs, better clinical outcomes (lower risk of chemother-
apy disruption and lower risk of infection), and greater conven-
ience (one G-CSF injection per chemotherapy cycle).
Although physicians are also likely to value improved clinical
outcomes when selecting a prophylactic G-CSF, the current study
found that total out-of-pocket cost per chemotherapy cycle had
the strongest effect on participants’ choices over any clinical
beneﬁts. Thus, short-term economic burden is a very important
consideration for many patients. In addition, while patients may
prefer the convenience and total out-of-pocket costs of shorter
courses of therapy, suboptimal use of ﬁlgrastim (i.e., six doses per
cycle) can lead to an increased risk of FN-related complications,
ultimately increasing patients’ out-of-pocket costs. It is impor-
tant for physicians and patients to balance the trade-offs
between out-of-pocket costs, clinical outcomes, and convenience
Table 3 – Estimated preference weights for each level of each attribute.
Estimated
preference weights
Standard
error
95% Wald
conﬁdence limits
Risk of disruption to chemotherapy schedule due to low white blood
cell counts (neutropenia)*
Low 0.366 0.026 (0.315–0.417)
Moderate 0.105 0.025 (0.056–0.154)
High† 0.471 0.027 (0.524 to 0.418)
Risk of developing an infection requiring hospitalization
7% 0.338 0.026 (0.287–0.389)
17% 0.011 0.025 (0.038 to 0.060)
24%† 0.349 0.026 (0.400 to 0.298)
Frequency of G-CSF administration‡
1 0.393 0.022 (0.350–0.436)
6 0.125 0.033 (0.190 to 0.060)
11† 0.268 0.033 (0.333 to 0.203)
Out-of-pocket cost for G-CSF support during a chemotherapy cycle ($)§
50 0.039 0.002 (0.043 to 0.035)
250 0.194 0.010 (0.214 to 0.175)
500 0.389 0.020 (0.427 to 0.350)
1000 0.777 0.040 (0.855 to 0.700)
1500 1.166 0.059 (1.282 to 1.050)
G-CSF, granulocyte colony-stimulating factor.
* Includes chemotherapy dose reductions and dose delays.
† Calculated as the negative sum of estimates of other levels within each attribute.
‡ Injections per cycle.
§ Includes all injections.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 8 0 – 3 8 9386of different G-CSF regimens, including the potential economic
impact associated with FN-related complications.
Although aggregate WTP is a useful indicator of how patients
value speciﬁc features of G-CSF treatment, individual patient
preferences should also be taken into consideration during
shared decision making. Participants with full-time employment
were willing to pay almost $300 more out of pocket to reduce the
number of G-CSF injections from 11 to 1 per cycle than were
participants who were unemployed. A patient’s ability to pay is
an important consideration; however, full-time employees mayFig. 2 – Relative importance of each attribute. This ﬁgure displa
attribute.be willing to pay more for the convenience of a single injection,
reducing time off work.
It is important to note that the WTP estimates must be
considered in the context of our DCE and are likely higher than
the actual out-of-pocket costs for G-CSF support. For example, a
recent study using US health care claims databases found that
the quarterly out-of-pocket costs for G-CSF use in cancer patients
who received chemotherapy between 2007 and 2010 were $100 to
$150 and $50 to $80 per patient for pegﬁlgrastim and ﬁlgrastim,
respectively (costs were adjusted to 2010 US dollars) [30].ys each attribute and the relative importance within each
Table 4 – Incremental WTP (US $) between levels of each attribute*.
Incremental WTP (US $) (95% CIs†)
n Risk of disruption to chemotherapy schedule‡ Risk of developing an infection requiring
hospitalization
Frequency of G-CSF
administration§
High to
moderate
Moderate to
low
High to low‖ 24% to 17% 17% to 7% 24% to 7%¶ 6 to 1 11 to 1
Full sample 296 741 (630–852) 335 (223–448) 1076 (940–1213) 464 (369–559) 420 (305–536) 884 (764–1005) 667 (551–783) 851 (711–991)
Age (y)
18–44 87 951 (599–1303) 515 (186–845) 1466 (996–1938) 590 (308–873) 247 (59 to 554) 837 (509–1167) 633 (315–950) 727 (358–1096)
45–54 69 639 (453–825) 366 (167–566) 1005 (775–1236) 359 (198–520) 542 (331–753) 901 (687–1116) 485 (297–674) 1,004 (742–1267)
55–64 96 706 (546–865) 243 (82–404) 949 (761–1136) 412 (277–547) 392 (226–559) 804 (636–973) 753 (577–930) 746 (549–943)
65þ 44 696 (421–971) 280 (3–557) 976 (650–1301) 578 (325–831) 523 (221–825) 1101 (756–1445) 779 (467–1091) 983 (607–1358)
Employment status
Full-time 116 1138 (860–1417) 682 (433–930) 1820 (1425–2216) 466 (279–653) 475 (246–705) 941 (695–1188) 689 (461–918) 1077 (772–1381)
Part-time 34 370 (107–633) 142 (174 to 457) 512 (223–799) 729 (408–1050) 481 (141–821) 1210 (782–1639) 714 (362–1065) 620 (253–988)
Unemployed 146 596 (470–723) 175 (40–311) 771 (630–913) 411 (296–526) 376 (235–518) 787 (646–928) 644 (501–787) 772 (604–940)
Neutropenia and FN
history
FN experience 68 507 (274–740) 323 (56–590) 830 (548–1112) 202 (2 to 406) 241 (22 to 505) 443 (220–667) 425 (174–677) 651 (345–957)
Neutropenia
experience
without FN
91 714 (530–898) 288 (100–477) 1002 (780–1224) 474 (311–637) 453 (259–648) 927 (716–1138) 683 (486–879) 840 (605–1076)
Combined
(neutropenia and/
or FN experience)
159 636 (491–781) 297 (142–452) 933 (758–1108) 370 (243–496) 368 (211–526) 738 (584–892) 585 (429–741) 765 (578–953)
FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor; WTP, willingness to pay.
* Missing responses due to skip patterns and “I don’t remember/don’t know” responses were omitted from the subgroup analysis.
† Wald conﬁdence intervals; Standard errors of WTP ratios approximated via delta method [52].
‡ Because of low white blood cell counts and includes chemotherapy dose reductions and dose delays.
§ Injections per cycle.
‖ Calculated by adding WTP for “high to moderate” and WTP for “moderate to low.”
¶ Calculated by adding WTP for “24% to17%” and WTP for “17% to 7%.”
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 8 0 – 3 8 9388While it is important to understand a patient’s preferences
independent of the physician’s perspective, we must acknowl-
edge the physician’s role in shaping those preferences. The
participants in our study appeared to recognize the importance
of maintaining dose intensity and decreasing the risk of devel-
oping an infection. The high value patients placed on maintain-
ing dose intensity is likely due to physicians educating patients
and their families regarding the clinical beneﬁts [8].
In terms of generalizability to the US population, 56% of the
study population was 45 to 64 years old, which is similar to the
Survey, Epidemiology, and End Results database in which 47% of
the patients diagnosed with breast cancer (2005 and 2009) were
within this age range [44]. In our study, 86% of the participants
were white and 8% were black, which is also similar to the racial
distribution of breast cancer reported in the Survey, Epidemiol-
ogy, and End Results database (88% vs. 8% [44]). Most of the
participants had a household income of less than $100,000 (76%),
similar to 2009 US Census Bureau estimates (80% [45]). A higher
proportion of participants in our study, however, had some form
of insurance coverage (private or public, 98%) compared with 2009
US Census Bureau estimates (83% [45]).
Several limitations of our study should be noted. Internet
surveys represent a convenience sampling frame and may not be
representative of the general population, and study participants
with Internet access may be different from those without Inter-
net access. While a low response (completion) rate was achieved,
it is important to note that the expected qualifying incidence
among survey panelists (e.g., breast cancer diagnosis and use of
chemotherapy for breast cancer within the past 5 years, Z18
years old, and willingness to sign informed consent) was esti-
mated at less than 1%. Therefore, it is assumed that a large
proportion of the panelists who received a study invitation were
not eligible to participate. In addition, the accuracy of the self-
reported information used for screening could not be veriﬁed.
Furthermore, the survey questions were designed to collect prior
experiences and/or clinical history and may be subject to recall
bias because accurate memory of events/details from the past 5
years may be challenging. We were unable to ﬁnd published
estimates of rates of disruption to patients’ chemotherapy sched-
ules; therefore, we used the categories “low,” “moderate,” and
“high” to represent the levels of this attribute. However, this
limits the interpretation of the preference-weight estimates of
these levels because participants may interpret these levels
differently, as well as limits the ability to interpret the results
in the context of an applied decision about treatments with
different rates of risk of disruption. Last, as a limitation of all
conjoint analyses, the trade-offs between the speciﬁc attributes
and levels as deﬁned in the survey may not depict patients’ real-
life choices.
Shared physician and patient decision making has been
shown to positively affect adherence to treatment and health
outcomes [46,47], and in clinical practice, physicians are encour-
aged to involve patients in treatment decisions [48]. The US Food
and Drug Administration and the European Medicines Agency
recognize the role of the patient perspective in weighing the risk/
beneﬁt of treatments and are considering ways to incorporate
patients’ perspectives into the regulatory framework for drug and
device approvals [49–51]. As evidenced by the substantial invest-
ment in the Patient Centered Outcomes Research Institute and
comparative effectiveness research, physicians should gain a
better understanding of patients’ preferences for various treat-
ment options and how they value treatment outcomes. The data
generated from DCEs can provide evidence of the perceived value
of treatment features (e.g., convenience and acceptable levels of
risk) from a patient’s perspective and can be used as supple-
mentary and/or complementary information for physicians to
consider when prescribing therapies.Conclusions
Patient treatment preferences are an important consideration in
the context of shared patient and physician decision making.
This study offers insight into the preferences of self-reported
breast cancer patients who have a history of chemotherapy with
respect to their options for prophylactic G-CSF support. Our
ﬁndings show that the attribute “total out-of-pocket costs for G-
CSF” had the greatest effect on participants’ choices, followed by
the attribute “risk of disruption to chemotherapy schedule (dose
reduction or chemotherapy delay),” “risk of developing an infec-
tion requiring hospitalization,” and “frequency of treatment.”Acknowledgments
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